31.51
-0.31(-0.97%)
Currency In USD
| Previous Close | 31.82 |
| Open | 31.63 |
| Day High | 31.86 |
| Day Low | 31.27 |
| 52-Week High | 60.37 |
| 52-Week Low | 25.81 |
| Volume | 1.23M |
| Average Volume | 1.97M |
| Market Cap | 3.04B |
| PE | -5.75 |
| EPS | -5.48 |
| Moving Average 50 Days | 30.39 |
| Moving Average 200 Days | 37.77 |
| Change | -0.31 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $260.35 as of September 09, 2025 at a share price of $31.51. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $412.81 as of September 09, 2025 at a share price of $31.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
GlobeNewswire Inc.
10 hours ago
At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance Phase 3 results are further supported by early data from
Ultragenyx to Participate at Investor Conferences in September
GlobeNewswire Inc.
Aug 29, 2025 8:30 PM GMT
NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
GlobeNewswire Inc.
Aug 18, 2025 12:00 PM GMT
Company expects to complete BLA submission in the fourth quarter of 2025NOVATO, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the initiation of a rolling submission of a Biologics License Ap